Insider Selling: Supernus Pharmaceuticals Inc (SUPN) VP Sells 20,000 Shares of Stock
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $48.04, for a total transaction of $960,800.00. Following the completion of the sale, the vice president now owns 32,500 shares of the company’s stock, valued at $1,561,300. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Supernus Pharmaceuticals Inc (SUPN) opened at $43.15 on Thursday. Supernus Pharmaceuticals Inc has a 12 month low of $24.05 and a 12 month high of $50.04. The company has a market cap of $2,210.00, a P/E ratio of 39.23 and a beta of 1.17.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. The firm’s revenue was up 41.5% on a year-over-year basis. research analysts forecast that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current year.
A number of analysts recently commented on SUPN shares. Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. FBR & Co started coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $53.00 target price for the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $49.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. B. Riley reiterated a “buy” rating and issued a $50.00 target price on shares of Supernus Pharmaceuticals in a research note on Monday, November 20th. Finally, Stifel Nicolaus upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, November 7th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $49.90.
TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/insider-selling-supernus-pharmaceuticals-inc-supn-vp-sells-20000-shares-of-stock/1822951.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.